nach oben

Digestive Diseases and Sciences

Erschienen in:

11.04.2016 | Review

Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma

verfasst von: Erik J. Snider, Daniel E. Freedberg, Julian A. Abrams

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Esophageal adenocarcinoma and its precursor Barrett’s esophagus have been rapidly increasing in incidence for half a century, for reasons not adequately explained by currently identified risk factors such as gastroesophageal reflux disease and obesity. The upper gastrointestinal microbiome may represent another potential cofactor. The distal esophagus has a distinct microbiome of predominantly oral-derived flora, which is altered in Barrett’s esophagus and reflux esophagitis. Chronic low-grade inflammation or direct carcinogenesis from this altered microbiome may combine with known risk factors to promote Barrett’s metaplasia and progression to adenocarcinoma.

Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499–2509. doi:10.1056/NEJMra1314530.CrossRefPubMed

Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383. doi:10.1056/NEJMoa1103042.CrossRefPubMed

Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057. doi:10.1093/jnci/djr203.CrossRefPubMedPubMedCentral

Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9:220–227. doi:10.1016/j.cgh.2010.11.008. (quiz e26).CrossRefPubMed

Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: Are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19:1468–1470. doi:10.1158/1055-9965.EPI-10-0012.CrossRefPubMed

Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162. doi:10.1093/annonc/mds181.CrossRefPubMed

Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–1187.CrossRefPubMedPubMedCentral

Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940–2007. Cancer Epidemiol Biomarkers Prev. 2011;20:183–186. doi:10.1158/1055-9965.EPI-10-0802.CrossRefPubMed

Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer. 1993;54:402–407.CrossRefPubMed

10.

Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42:17–22. doi:10.1080/00365520600815654.CrossRefPubMed

11.

Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26:739–745. doi:10.1007/s10654-011-9596-z.CrossRefPubMed

12.

van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett’s oesophagus in the general population. Gut. 2005;54:1062–1066. doi:10.1136/gut.2004.063685.CrossRefPubMedPubMedCentral

13.

Petrick JL, Nguyen T, Cook MB. Temporal trends of esophageal disorders by age in the Cerner Health Facts database. Ann Epidemiol. 2016;26:151–154 e4. doi:10.1016/j.annepidem.2015.11.004.CrossRefPubMed

14.

Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572. doi:10.1016/j.cgh.2006.03.001.CrossRefPubMed

15.

den Hoed CM, van Blankenstein M, Dees J, Kuipers EJ. The minimal incubation period from the onset of Barrett’s oesophagus to symptomatic adenocarcinoma. Br J Cancer. 2011;105:200–205. doi:10.1038/bjc.2011.214.CrossRef

16.

Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–1413.CrossRefPubMed

17.

El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17–26. doi:10.1016/j.cgh.2006.09.016.CrossRefPubMed

18.

el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43:327–333.CrossRefPubMedPubMedCentral

19.

Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord. 1998;22:39–47.CrossRefPubMed

20.

Kong CY, Nattinger KJ, Hayeck TJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev.. 2011;20:2450–2456. doi:10.1158/1055-9965.EPI-11-0547.CrossRefPubMedPubMedCentral

21.

Giovino GA. Epidemiology of tobacco use in the United States. Oncogene. 2002;21:7326–7340. doi:10.1038/sj.onc.1205808.CrossRefPubMed

22.

Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–1353. doi:10.1093/jnci/djq289.CrossRefPubMedPubMedCentral

23.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.CrossRefPubMed

24.

Lagergren K, Lindam A, Lagergren J. Dietary proportions of carbohydrates, fat, and protein and risk of oesophageal cancer by histological type. PLoS ONE. 2013;8:e54913. doi:10.1371/journal.pone.0054913.CrossRefPubMedPubMedCentral

25.

Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21. doi:10.1111/j.1753-4887.2011.00456.x.CrossRefPubMedPubMedCentral

26.

Austin GL, Ogden LG, Hill JO. Trends in carbohydrate, fat, and protein intakes and association with energy intake in normal-weight, overweight, and obese individuals: 1971-2006. Am J Clin Nutr. 2011;93:836–843. doi:10.3945/ajcn.110.000141.CrossRefPubMed

27.

Wright JD, Wang CY. Trends in intake of energy and macronutrients in adults from 1999–2000 through 2007–2008. NCHS Data Brief. 2010;49:1–8.PubMed

28.

Centers for Disease C, Prevention. Trends in intake of energy and macronutrients—United States, 1971–2000. MMWR Morb Mortal Wkly Rep. 2004;53:80–82.

29.

Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov. 2013;12:371–387. doi:10.1038/nrd3975.CrossRefPubMed

30.

Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1:329–338. doi:10.1158/1940-6207.CAPR-08-0109.CrossRef

31.

Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis. 1993;168:219–221.CrossRefPubMed

32.

Rehnberg-Laiho L, Rautelin H, Koskela P, et al. Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect. 2001;126:37–42.PubMedPubMedCentral

33.

Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014;146:1534–1546.e3. doi:10.1053/j.gastro.2014.01.001.CrossRefPubMedPubMedCentral

34.

Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–812. doi:10.1038/nrc3610.CrossRefPubMedPubMedCentral

35.

Fraher MH, O’Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol. 2012;9:312–322. doi:10.1038/nrgastro.2012.44.CrossRefPubMed

36.

Smith JL, Bayles DO. The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol. 2006;32:227–248. doi:10.1080/10408410601023557.CrossRefPubMed

37.

Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–123. doi:10.1126/science.1224820.CrossRefPubMedPubMedCentral

38.

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206. doi:10.1016/j.chom.2013.07.012.CrossRefPubMedPubMedCentral

39.

Lau WF, Wong J, Lam KH, Ong GB. Oesophageal microbial flora in carcinoma of the oesophagus. Aust N Z J Surg. 1981;51:52–55.CrossRefPubMed

40.

Finlay IG, Wright PA, Menzies T, McArdle CS. Microbial flora in carcinoma of oesophagus. Thorax. 1982;37:181–184.CrossRefPubMedPubMedCentral

41.

Mannell A, Plant M, Frolich J. The microflora of the oesophagus. Ann R Coll Surg Engl. 1983;65:152–154.PubMedPubMedCentral

42.

Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci USA. 2004;101:4250–4255. doi:10.1073/pnas.0306398101.CrossRefPubMedPubMedCentral

43.

Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol. 2010;192:5002–5017. doi:10.1128/JB.00542-10.CrossRefPubMedPubMedCentral

44.

Osias GL, Bromer MQ, Thomas RM, et al. Esophageal bacteria and Barrett’s esophagus: a preliminary report. Dig Dis Sci. 2004;49:228–236.CrossRefPubMed

45.

Macfarlane S, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patients with Barrett’s esophagus. Clin Infect Dis. 2007;45:29–38. doi:10.1086/518578.CrossRefPubMed

46.

Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588–597. doi:10.1053/j.gastro.2009.04.046.CrossRefPubMedPubMedCentral

47.

Liu N, Ando T, Ishiguro K, et al. Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett’s esophagus. BMC Infect Dis. 2013;13:130. doi:10.1186/1471-2334-13-130.CrossRefPubMedPubMedCentral

48.

Gall A, Fero J, McCoy C, et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett’s esophagus cohort. PLoS ONE. 2015;10:e0129055. doi:10.1371/journal.pone.0129055.CrossRefPubMedPubMedCentral

49.

Narikiyo M, Tanabe C, Yamada Y, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci. 2004;95:569–574.CrossRefPubMed

50.

Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: Association or causality? Aliment Pharmacol Ther. 2013;37:1084–1092. doi:10.1111/apt.12317.CrossRefPubMed

51.

Clarke AT, Wirz AA, Seenan JP, Manning JJ, Gillen D, McColl KE. Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic. Gut. 2009;58:904–909. doi:10.1136/gut.2008.161927.CrossRefPubMed

52.

McDonald SA, Lavery D, Wright NA, Jansen M. Barrett oesophagus: lessons on its origins from the lesion itself. Nat Rev Gastroenterol Hepatol. 2015;12:50–60. doi:10.1038/nrgastro.2014.181.CrossRefPubMed

53.

Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21:36–51. doi:10.1016/j.ccr.2011.12.004.CrossRefPubMedPubMedCentral

54.

Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403–414. doi:10.1038/nrc2857.CrossRefPubMedPubMedCentral

55.

Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12:239–245. doi:10.1016/j.cgh.2013.08.029.CrossRefPubMed

56.

Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA. 2006;103:732–737. doi:10.1073/pnas.0506655103.CrossRefPubMedPubMedCentral

57.

Tian Z, Yang Z, Gao J, Zhu L, Jiang R, Jiang Y. Lower esophageal microbiota species are affected by the eradication of infection using antibiotics. Exp Ther Med. 2015;9:685–692. doi:10.3892/etm.2015.2169.PubMedPubMedCentral

58.

Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE. 2008;3:e2836. doi:10.1371/journal.pone.0002836.CrossRefPubMedPubMedCentral

59.

Li XX, Wong GL, To KF, et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS ONE. 2009;4:e7985. doi:10.1371/journal.pone.0007985.CrossRefPubMedPubMedCentral

60.

Stearns JC, Lynch MD, Senadheera DB, et al. Bacterial biogeography of the human digestive tract. Sci Rep. 2011;1:170. doi:10.1038/srep00170.CrossRefPubMedPubMedCentral

61.

Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5:574–579. doi:10.1038/ismej.2010.149.CrossRefPubMed

62.

Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2015. doi:10.1136/gutjnl-2015-310861.PubMedPubMedCentral

63.

Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015. doi:10.1053/j.gastro.2015.06.043.

64.

Rosen R, Amirault J, Liu H, et al. Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatr. 2014;168:932–937. doi:10.1001/jamapediatrics.2014.696.CrossRefPubMed

65.

David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563. doi:10.1038/nature12820.CrossRefPubMed

66.

Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014;146:1564–1572. doi:10.1053/j.gastro.2014.01.058.CrossRefPubMedPubMedCentral

67.

Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature. 2014;514:508–512. doi:10.1038/nature13398.CrossRefPubMedPubMedCentral

68.

O’Keefe SJ, Li JV, Lahti L, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342. doi:10.1038/ncomms7342.CrossRefPubMedPubMedCentral

69.

Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol. 2000;165:3541–3544.CrossRefPubMed

70.

O’Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257–1264. doi:10.1111/j.1572-0241.2005.41338.x.CrossRefPubMed

71.

Calatayud S, Garcia-Zaragoza E, Hernandez C, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1360–G1367. doi:10.1152/ajpgi.00168.2002.CrossRefPubMed

72.

Fan YP, Chakder S, Gao F, Rattan S. Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Am J Physiol Gastrointest Liver Physiol. 2001;280:G32–G42.PubMed

73.

Suzuki H, Iijima K, Scobie G, Fyfe V, McColl KE. Nitrate and nitrosative chemistry within Barrett’s oesophagus during acid reflux. Gut. 2005;54:1527–1535. doi:10.1136/gut.2005.066043.CrossRefPubMedPubMedCentral

Titel: Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma
verfasst von: Erik J. Snider
Daniel E. Freedberg
Julian A. Abrams
Publikationsdatum: 11.04.2016
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 8/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-016-4155-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

GI-Safer Aspirin: Sometimes Sugar Coating Helps

Resolution of Isolated, Aspergillus Colonization in a Deep Esophageal Ulcer in an Immunocompetent Patient with Ulcer Healing Without Specific Antifungal Therapy

Amoxicillin–Clavulanate-Induced Liver Injury

Gastric Variceal Bleeding Caused by an Arterioportal Fistula Formation After TIPS and Related Complications

Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?

Mellow Yellow: Diagnosis and Management of Multifactorial Postoperative Jaundice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin